Immuneering（IMRX）株式概要
イミュニアリング・コーポレーションは後期癌治療薬開発企業で、米国で幅広い癌患者を対象に医薬品を開発している。 詳細
IMRX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Immuneering Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$5.20 |
| 52週高値 | US$10.08 |
| 52週安値 | US$3.00 |
| ベータ | 0.37 |
| 1ヶ月の変化 | 0.78% |
| 3ヶ月変化 | 0.78% |
| 1年変化 | 38.30% |
| 3年間の変化 | -41.96% |
| 5年間の変化 | -82.91% |
| IPOからの変化 | -70.44% |
最新ニュース
Seeking Alpha • Jul 27
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking Alpha分析記事 • Jun 30
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Recent updates
Seeking Alpha • Jul 27
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking Alpha分析記事 • Jun 30
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
新しいナラティブ • Mar 19
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
Catalysts About Immuneering Immuneering is a biotechnology company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer and other tumor types. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Mar 05
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
Catalysts About Immuneering Immuneering is a clinical stage biotech company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer. What are the underlying business or industry changes driving this perspective?分析記事 • Nov 22
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Immuneering...分析記事 • Jul 01
Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Mar 18
Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Aug 30
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 13
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Mar 19
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Summary Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024. Immuneering had $85.7 million in cash as of December 31st of 2023; Enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking Alpha分析記事 • Jan 06
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Aug 17
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 30
Immuneering wins FDA nod to study lead asset in solid tumors
The development-stage biotech Immuneering Corporation (NASDAQ:IMRX) announced Friday that the FDA greenlighted its Investigational New Drug (IND) application to study IMM-1-104, its lead candidate targeted at advanced RAS mutant solid tumors. Accordingly, the company expects to begin a Phase 1/2a clinical trial to assess the oral, once-daily therapy in advanced RAS mutant solid tumors across five clinical sites in the U.S. IMRX expects to follow the Phase 1 segment of the study with a dose expansion Phase 2a portion targeted at RAS mutated pancreatic, melanoma, colorectal, and lung cancers. The first patient is expected to enroll in Q4 2022. “Clearance of the IND for IMM-1-104 brings us one step closer to our goal of developing medicines with the potential to benefit every cancer patient with a RAS mutant solid tumor, not just those harboring specific mutations,” Chief Executive Ben Zeskind said. The announcement of the IND submission for IMM-1-104 sent IMRX shares higher early this month.Seeking Alpha • Sep 02
Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
The shares of development-stage biotech Immuneering Corporation (NASDAQ:IMRX) added ~9% in the pre-market trading Friday after the company announced the filing of an Investigational New Drug (IND) seeking FDA clearance to conduct a clinical trial for its lead asset IMM-1-104. An oral once-daily small molecule, IMM-1-104, targets advanced solid tumors with RAS mutations, unlike the candidates that target specific cancer mutations such as KRAS-G12C. “The preclinical data package for IMM-1-104 is uniquely compelling, and we are excited to now evaluate this compound in patients who so urgently need new options,” the Chief Executive of IMRX, Brett Hall, noted. With the IND submission, the FDA will review the company’s application to determine if the data support the safety of IMM-1-104. IMRX plans to conduct a Phase 1/2a clinical trial of IMM-1-104 across five internationally recognized clinical sites in the U.S. Amgen (AMGN) and Mirati Therapeutics (MRTX) are among the developers of cancer therapies targeted at KRAS G12C mutations.Seeking Alpha • Jul 08
Immuneering initiated a Buy by Chardan, PT set to $18
Immuneering (NASDAQ:IMRX) initiated with a Buy by Chardan analyst Geulah Livshits and gave $18 as price target. The analyst likes the potential of Immuneering's pipeline and translational bioinformatics platform to address unmet needs in diverse cancers. The company's approach integrates analysis of high-throughput transcriptional, genomics, and proteomics datasets to generate insights into tumor signaling dynamics, and mechanisms of therapy response or resistance, to advance drug candidates with optimal signaling profiles, Livshits tells investors in a research note. Currently, the stock is trading at $6.3, a rise of ~10.7% on Friday. Stock has slumped about 64% over the last one year and company has a market cap of $139M . The stock is given a Wall Street 'Strong Buy' rating with 4.5 score (4 Strong Buy, 1 Buy, 1 Hold) Comparative rating of the stock against the peers:株主還元
| IMRX | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 15.3% | 2.5% | 1.7% |
| 1Y | 38.3% | 37.4% | 20.0% |
業界別リターン: IMRX過去 1 年間で37.4 % のリターンをもたらしたUS Biotechs業界と一致しました。
リターン対市場: IMRX過去 1 年間で20 % の収益を上げたUS市場を上回りました。
価格変動
| IMRX volatility | |
|---|---|
| IMRX Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: IMRXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: IMRXの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2008 | 57 | Ben Zeskind | immuneering.com |
イミュニアリング・コーポレーションは後期癌治療薬開発企業であり、米国において幅広い癌患者を対象とした医薬品を開発している。同社は、RASまたはRAFの変異に起因する膵臓がんや非小細胞肺がんなどのがん患者を対象に第3相臨床試験中のデュアルMEK阻害剤IMM-1-104（atebimetinib）、固形がん患者の治療を対象に第1/2a相臨床試験中のIMM-6-415（envometinib）、および複数の深部環状阻害剤探索プログラムを開発している。同社は、切除不能または転移性のRAS変異非小細胞肺がん患者を対象に、アテビメチニブとリブタヨの併用療法を評価するためにリジェネロン・ファーマシューティカルズと、進行性または転移性のKRAS G12C変異非小細胞肺がん患者を対象にアテビメチニブとオロモラシブの併用療法を評価するためにイーライリリー・アンド・カンパニーと臨床供給契約を結んでいる。Immuneering Corporationは2008年に設立され、マサチューセッツ州ケンブリッジに本社を置いている。
Immuneering Corporation 基礎のまとめ
| IMRX 基礎統計学 | |
|---|---|
| 時価総額 | US$336.43m |
| 収益（TTM） | -US$57.28m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-5.9x
PER（株価収益率IMRX は割高か？
公正価値と評価分析を参照収益と収入
| IMRX 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$0 |
| 売上総利益 | US$0 |
| その他の費用 | US$57.28m |
| 収益 | -US$57.28m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.89 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
IMRX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/14 22:07 |
| 終値 | 2026/08/13 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Immuneering Corporation 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Andres Maldonado | H.C. Wainwright & Co. |